Earnings summaries and quarterly performance for Viatris.
Executive leadership at Viatris.
Board of directors at Viatris.
DS
David Simmons
Detailed
Director
EF
Elisha Finney
Detailed
Director
FD
Frank D’Amelio
Detailed
Director
HK
Harry Korman
Detailed
Director
JM
James M. Kilts
Detailed
Director
JL
JoEllen Lyons Dillon
Detailed
Director
LG
Leo Groothuis
Detailed
Director
MP
Mark Parrish
Detailed
Vice Chair of the Board
MH
Melina Higgins
Detailed
Chair of the Board
MS
Michael Severino
Detailed
Director
RM
Rajiv Malik
Detailed
Director
RM
Richard Mark
Detailed
Director
RV
Rogério Vivaldi Coelho
Detailed
Director
WD
W. Don Cornwell
Detailed
Director
Research analysts who have asked questions during Viatris earnings calls.
David Amsellem
Piper Sandler Companies
6 questions for VTRS
Also covers: ABBV, ALKS, AMGN +27 more
AV
Ashwani Verma
UBS Group AG
5 questions for VTRS
Also covers: ACAD, ALKS, ALVO +12 more
CS
Christopher Schott
JPMorgan Chase & Co.
5 questions for VTRS
Also covers: ABBV, AMGN, AMRX +15 more
Jason Gerberry
Bank of America Merrill Lynch
4 questions for VTRS
Also covers: ALKS, AMPH, ARWR +21 more
UR
Umer Raffat
Evercore ISI
4 questions for VTRS
Also covers: ALKS, AMGN, BHC +15 more
MD
Matt Dellatorre
Goldman Sachs
3 questions for VTRS
BP
Balaji Prasad
Barclays
2 questions for VTRS
Also covers: ALVO, AMRX, ELAN +7 more
JG
Jason Gerbery
Bank of America
2 questions for VTRS
Also covers: IONS
LS
Leszek Sulewski
Truist Securities
2 questions for VTRS
Also covers: AKBA, AMRX, ANIP +6 more
AV
Ash Verma
UBS
1 question for VTRS
Also covers: ALVO, AVDL, EXEL +6 more
J
JP
Evercore ISI
1 question for VTRS
LW
Li Wenwen
Danasting
1 question for VTRS
Recent press releases and 8-K filings for VTRS.
Viatris launches Inpefa in UAE
VTRS
Product Launch
- Viatris launched Inpefa (sotagliflozin) in the UAE, the first country in its territories to commercialize the dual SGLT1/2 inhibitor for heart failure treatment.
- Inpefa, approved to reduce cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease or other cardiovascular risk factors, is the first and only dual SGLT1/2 inhibitor for heart failure.
- Approval was based on Phase 3 trials: SOLOIST-WHF showed a 33% reduction in the composite risk of heart failure hospitalization, urgent visits and cardiovascular death (up to 51% when initiated pre-discharge); SCORED showed a 25% reduction in the same endpoint; MACE was reduced by 23%, MI by 32% and stroke by 34%.
- Viatris plans additional launches over the next several years and has submitted regulatory filings in Canada, Australia and Mexico to expand global access.
Jan 20, 2026, 11:59 AM
Viatris outlines 2026 growth strategy at J.P. Morgan Healthcare Conference
VTRS
Product Launch
Share Buyback
M&A
- Viatris reported $14.1 billion in 2025 revenue, $4.1 billion EBITDA, and $2.2 billion in free cash flow in the last 12 months, serving over 1 billion patients in 165 countries.
- The base generics and established brands business has stabilized with 1–2% revenue growth over the past eight to ten quarters, and management expects to drive mid-single-digit revenue growth in 2026 through planned launches and accretive in-market business development.
- A robust pipeline and launch slate is set for 2026, including fast-acting meloxicam, sotagliflozin, pitolisant and Spidifen in Japan, Effexor GAD, plus Phase 3 readouts for cenerimod and selatogrel expected late 2026/early 2027.
- An enterprise-wide strategic review aims to optimize procurement, marketing and development, delivering net savings to the bottom line; cash flow will be allocated roughly 50/50 between dividends/share buybacks and business development.
Jan 13, 2026, 5:00 PM
Viatris outlines 2026 growth strategy at J.P. Morgan Healthcare Conference
VTRS
Guidance Update
Product Launch
M&A
- Over the past 12 months, Viatris delivered $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow across 165 countries with 1,400 products.
- Management returned over $1 billion to shareholders through dividends and share buybacks and initiated an Enterprise-Wide Strategic Review to streamline operations and reinvest savings.
- The company expects to shift to mid-single-digit revenue growth in 2026, supported by upcoming launches and net savings from the strategic review beginning to drop to the bottom line.
- Key 2026 launches include sotagliflozin, fast-acting meloxicam, low-dose estrogen patch, and in Japan: Spidifen, Pitolisant, Effexor GAD, plus an eye-care treatment for presbyopia.
- Viatris is targeting $500 million–$1 billion peak-revenue assets via ~60 regional deals annually, with emphasis on accretive U.S. in-market and Japan business development.
Jan 13, 2026, 5:00 PM
Viatris outlines 2026 strategy and pipeline at JPM Healthcare Conference
VTRS
Product Launch
M&A
Share Buyback
- Viatris reported $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow for 2025, operating in 165 countries and serving over 1 billion patients annually.
- The company achieved 5 of 6 positive Phase 3 readouts in 2025 and advanced key pipeline assets (Cenerimod, Selatogrel, Lucerastat), with planned 2026 launches of sotagliflozin, fast-acting meloxicam, Pitolisant, Spidifen, and Effexor GAD.
- An Enterprise-Wide Strategic Review completed in 2025 aims to optimize the organizational structure, with significant cost savings expected to begin flowing through in 2026 and support mid-single-digit revenue growth.
- Viatris executed 60 regional business development deals in 2025, is targeting accretive U.S. assets ($500 million–$1 billion peak sales), expanded its Japan portfolio via the Oculus acquisition, and plans a 50/50 split of free cash flow between shareholder returns and M&A over the next 3–5 years.
- Remediation at the Indore manufacturing facility is ~90% complete; FDA reinspection timing is pending, but built-in redundancies should limit operational volatility in 2026.
Jan 13, 2026, 5:00 PM
Viatris outlines 2025 financial results and 2026 strategic priorities
VTRS
Product Launch
Guidance Update
- 12 months ended September 30, 2025: Total revenues of $14.1 billion, adjusted EBITDA of $4.1 billion, adjusted EPS of $2.32, and free cash flow ex-transaction costs of $2.2 billion.
- Global footprint: operations in 165+ countries, 26 manufacturing facilities, ~1,400 approved molecules, serving ~1 billion patients annually.
- Achieved key 2025 milestones: completed five positive Phase 3 readouts, over $1 billion returned to shareholders, and acquisition of Aculys Pharma in Japan.
- 2026 strategic setup: anticipated launches (e.g., sotagliflozin in H1 2026, low-dose estrogen patch in H2 2026), enterprise-wide cost savings, and pipeline milestones for cenerimod and selatogrel.
Jan 13, 2026, 5:00 PM
vVARDIS presents drill-free early cavity treatment at 2026 J.P. Morgan Healthcare Conference
VTRS
Product Launch
New Projects/Investments
- vVARDIS founders Drs. Haley and Goly Abivardi showcased Curodont™, a drill-free early cavity treatment—with over 2 million teeth treated in 24 months—at the 2026 J.P. Morgan Healthcare Conference.
- Emphasized recognition by Jamie Dimon at the 2025 event and vVARDIS’ status as the fastest-growing dental product in the U.S. preventive category.
- Launched the “Save Teeth Save Lives” global cavity awareness campaign, symbolized by a turquoise ribbon, to promote early, non-invasive cavity intervention.
- Highlighted recent momentum with $85 million in funding from OrbiMed and expanded partnership with Henry Schein, supporting Curodont’s rollout in 12 percent of U.S. dental offices.
- Earned Dental Advisor’s 2026 Innovative Company of the Year award and Research Award for Curodont Repair Fluoride Plus.
Jan 12, 2026, 5:35 PM
Viatris provides pipeline update on four regulatory milestones
VTRS
Product Launch
New Projects/Investments
- FDA approval of generic octreotide acetate LAR depot injectable suspension for acromegaly and carcinoid tumour indications
- FDA acceptance of NDA for a once-weekly low-dose estrogen patch (150 mcg norelgestromin/17.5 mcg ethinyl estradiol) with a PDUFA target date of July 30, 2026
- FDA clearance of IND for MR-146 AAV gene therapy in neurotrophic keratopathy, with a Phase 1/2 CORVITA trial planned in H1 2026
- PMDA acceptance of J-NDA for pitolisant in obstructive sleep apnea syndrome; narcolepsy J-NDA submission expected by year-end 2025
Dec 18, 2025, 11:59 AM
Viatris announces monetization of Biocon Biologics stake
VTRS
M&A
- Viatris will sell its convertible preferred equity in Biocon Biologics for $815 million total consideration: $400 million in cash and $415 million in newly issued Biocon Limited shares.
- The agreement accelerates biosimilars non-compete restrictions, which will lapse immediately for ex-U.S. markets and in November 2026 for U.S. markets.
- The transaction is expected to close in Q1 2026, subject to customary closing conditions.
- Citi is acting as financial advisor, with Cravath, Swaine & Moore LLP and Khaitan & Co. as legal advisors to Viatris.
Dec 8, 2025, 12:00 PM
Viatris to monetize Biocon Biologics stake
VTRS
M&A
Convertible Preferred Issuance
- Viatris enters agreements to sell its convertible preferred equity stake in Biocon Biologics for $815 million total consideration ($400 million cash + $415 million Biocon shares).
- Shares are subject to a six-month lock-up and will trade on the National Stock Exchange of India.
- The deal accelerates expiration of biosimilars non-compete restrictions, effective at close outside the U.S. and in November 2026 for U.S. markets.
- The transaction is expected to close in Q1 2026, pending satisfaction of closing conditions.
Dec 6, 2025, 2:00 PM
Viatris outlines strategic review and growth plan at Evercore HealthCONx Conference
VTRS
Guidance Update
New Projects/Investments
- Viatris is executing an enterprise-wide strategic review to optimize cost structure and position for sustained revenue and earnings growth beyond 2026.
- The company expects its base business to generate approximately $200 million of net annual growth, supplemented by innovative assets from its pipeline and M&A activity.
- Over a three-year period, Viatris aims to capture significant, sticky cost savings—after allowing for reinvestment—with the majority flowing through to the bottom line.
- It plans to deploy about $2 billion in annual free cash flow equally between shareholder returns (dividends and buybacks) and building its growth pipeline.
- Key pipeline highlights include fast-acting meloxicam for acute pain with an opioid-sparing claim expected, and on-demand antiplatelet selatogrel for acute MI, both in late-stage development and targeted for launch in late 2026.
Dec 3, 2025, 1:45 PM
Quarterly earnings call transcripts for Viatris.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more